Summary
Regeneron Pharmaceuticals, Inc. (REGN) announced a significant leadership transition in its upcoming 2023 Annual Meeting of Shareholders. Dr. P. Roy Vagelos, the current Chair of the Board, has decided not to stand for re-election. This marks the end of his tenure, during which he will continue to serve until the conclusion of the meeting on June 9, 2023. The company has stated that Dr. Vagelos's decision was not due to any disagreements regarding the company's operations or policies.
Key Highlights
- 1P. Roy Vagelos, M.D., Chair of the Board, will not seek re-election at the June 9, 2023 Annual Meeting.
- 2Dr. Vagelos will continue to serve as Chair until the conclusion of the Annual Meeting.
- 3Upon Dr. Vagelos's departure, Leonard S. Schleifer, M.D., Ph.D. (President and CEO) and George D. Yancopoulos, M.D., Ph.D. (President and Chief Scientific Officer) are planned to be elected as Co-Chairs of the Board.
- 4Christine A. Poon is designated to serve as the Lead Independent Director.
- 5Dr. Vagelos's decision was not prompted by any disagreements with the company.
- 6The leadership change is effective after the 2023 Annual Meeting.